Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Converting Liver Tumors into Low-Oxygen Environment to Activate Drug to Drive Cell Death with Dr. Ray Lee Teclison TRANSCRIPT
Download PDFNov 14, 2022
Dr. Ray Lee is the CEO of Teclison, focused on overcoming the limitations of existing immunotherapy for treating liver cancer in part caused by the fact that the liver is a highly immunotolerant organ. The key is to make the tumor a low-oxygen environment and delivering a drug that only works on the tumor.
Ray elaborates, "First, let me explain what the TATE represents. It stands for the Trans-arterial TEC-001 Embolization. TEC-001 is the pipeline compound we've been trying to develop. This compound is a so-called prodrug. In other words, by itself, it has a low activity. But once in the low-oxygen environment, the drug is going to be activated. What we're trying to develop is to create a very innovative way to convert the tumor into an environment with low oxygen. And this low-oxygen environment is exclusive within the tumor but not in the normal liver nor in the systemic organs."
"So once they have this catheter in place, they will inject our drugs, the TEC-001, directly through the catheter into the tumor and then follow by the embolization. And what I mean by embolization is injecting a special kind of material, like a block in the tumor vessel, and cutting off the blood flow. So that means the tumor is no longer able to receive any blood, so they are not getting enough nutrients or oxygen, which makes the tumor be in a very low-oxygen environment. And that is how our drug is going to be almost immediately activated within the tumor after the embolization procedure, and that's how it works."
#Teclison #LiverCancer #Cancer #SolidTumors #Immunotherapy #CancerImmunotherapy #LiverMetastasis #LungCancer #ColorectalCancer
